Primary- and intermediate product plants for IgM Concentrate and polyvalent immunoglobulin G
New blood plasma systems for rising demand
Blood plasma is a very precious liquid as it builds the basis for live-saving medicines. According to the WHO, 14 million litres a year are processed worldwide – with rising demand. Biotest alone processes around one million litres a year. The producer of products out of plasma proteins as immunglobins, clotting factors and albumins raised its production capacity to 2,5 million liters with a new production builing with its own energy center. Thanks to their investment project “Biotest Next Level” of 250 Million Euros, they createe 300 additional employements.
Four plant units for processing blood plasma with different process steps
Detail engineering, programming and realisation
Components, pipe installation, controlling and qualification
The sheer size of the project was a challenge itself. With around 3,500 components, amongst them 2,300 automatised valves and 1,800 measuring- and controlling components, 100 pumps and agitators as well as more than 40 tanks, the project calls for a big team – at peak times 35 technicians and engineers from Ruland worked at Biotest. For the consistent automation of the four independent plants more than 30 load cabinets as well as more than 90 decentralised control cabinets for the connection of the valve terminal and field signals to the eight controls from Siemens were installed. The piping also impresses: nearly 9 km process leading pipes and media supply lines were laid, made out of various stainless steels at pharma-performance and partly out of high corrosion- resistant Hastelloy 22 or PVDF plastic lines. The 39,000 welds were documented in compliance with pharmaceutical standards.